Fig. 4

Patients with ROS1-rearranged NSCLC who had baseline brain metastasis still benefit from first-line crizotinib than chemotherapy. Kaplan-Meier survival curves illustrating the PFS for patients with ROS1-rearranged NSCLC who had non-brain metastasis (green) and brain metastasis (red) at baseline and received chemotherapy (A) and crizotinib (B) as first-line therapy. C Plot comparing the cumulative incidence of CNS progression in patients receiving crizotinib (green) and chemotherapy (red). D–E Crizotinib-treated patients with ROS1-rearranged NSCLC who experienced CNS only progression had a better prognosis than those who experienced non-CNS progression. D-E. Kaplan-Meier survival curves comparing the PFS of crizotinib-treated patients with ROS1-rearranged NSCLC who had non-CNS only progression (red), CNS only progression (green) and the whole cohort (blue) (D); E crizotinib-treated patients without baseline CNS metastasis who had CNS only progression (green) and non-CNS only progression (pink) and patients with baseline CNS metastasis who had CNS only progression (blue) and non-CNS only progression (red). The risk table below summarizes the number of patients included per time point